Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Go Kaneko

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Cureus|June 13, 2024
Choroidal Metastasis From Papillary Renal Cell Carcinomas: A Case Report and a Review of the LiteratureShinnosuke Hiruta, Go Kaneko, Yu Miyama, et al.
International Journal of Clinical Oncology|July 7, 2025
Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective studyDaiki Ikarashi, Nozomi Hayakawa, Go Kaneko, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 3, 2026
Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter StudyYuki Endo, Yuma Sakura, Go Kaneko, et al.
IJU Case Reports|May 5, 2022
Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinibKoshiro Nishimoto, Suguru Shirotake, Yu Miyama, et al.
Case Reports in Oncology|January 2, 2026
Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Case ReportKenta Fujii, Suguru Shirotake, Shohei Yamamura, et al.
Japanese Journal of Clinical Oncology|June 29, 2024
Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective studyNozomi Hayakawa, Eiji Kikuchi, Go Kaneko, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2025
Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinomaMaki Todo, Yodo Gatate, Shintaro Nakano, et al.
IJU Case Reports|November 7, 2022
Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcomeKoshiro Nishimoto, Noriaki Lukas Santo, Masato Yonamine, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 11, 2018
Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) studyKenichi Nakajima, Go Kaneko, Satoru Takahashi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 20, 2021
Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort studyKenichi Nakajima, Atsushi Mizokami, Hideyasu Matsuyama, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Cureus|June 13, 2024
Choroidal Metastasis From Papillary Renal Cell Carcinomas: A Case Report and a Review of the LiteratureShinnosuke Hiruta, Go Kaneko, Yu Miyama, et al.
International Journal of Clinical Oncology|July 7, 2025
Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective studyDaiki Ikarashi, Nozomi Hayakawa, Go Kaneko, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 3, 2026
Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter StudyYuki Endo, Yuma Sakura, Go Kaneko, et al.
IJU Case Reports|May 5, 2022
Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinibKoshiro Nishimoto, Suguru Shirotake, Yu Miyama, et al.
Case Reports in Oncology|January 2, 2026
Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Case ReportKenta Fujii, Suguru Shirotake, Shohei Yamamura, et al.
Japanese Journal of Clinical Oncology|June 29, 2024
Association between response to enfortumab vedotin and peripheral neuropathy in urothelial carcinoma patients: a multicenter retrospective studyNozomi Hayakawa, Eiji Kikuchi, Go Kaneko, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2025
Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinomaMaki Todo, Yodo Gatate, Shintaro Nakano, et al.
IJU Case Reports|November 7, 2022
Progressive metastatic pheochromocytoma induced by multiple endocrine neoplasia type 2A with a lethal outcomeKoshiro Nishimoto, Noriaki Lukas Santo, Masato Yonamine, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 11, 2018
Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI) studyKenichi Nakajima, Go Kaneko, Satoru Takahashi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 20, 2021
Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort studyKenichi Nakajima, Atsushi Mizokami, Hideyasu Matsuyama, et al.
Pageof 4